Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s share price fell 3.2% on Wednesday . The company traded as low as $10.77 and last traded at $10.78. 1,158 shares changed hands during trading, a decline of 81% from the average session volume of 6,180 shares. The stock had previously closed at $11.14.
Wall Street Analyst Weigh In
A number of research firms have weighed in on PHAR. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th. HC Wainwright reissued a "buy" rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Thursday, March 20th.
Check Out Our Latest Stock Report on Pharming Group
Pharming Group Stock Down 2.3%
The company has a current ratio of 2.76, a quick ratio of 2.00 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $721.12 million, a price-to-earnings ratio of -53.00 and a beta of 0.02. The firm's 50 day simple moving average is $9.93 and its 200-day simple moving average is $9.28.
Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.03. The company had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. On average, sell-side analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
